Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo

Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo

Abstract Background Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular...

Full description

Bibliographic Details
Main Authors: Ditte Reker, Cecilie F. Kjelgaard-Petersen, Anne Sofie Siebuhr, Martin Michaelis, Anne Gigout, Morten A. Karsdal, Christoph Ladel, Anne C. Bay-Jensen
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Journal of Translational Medicine
Subjects:
Osteoarthritis
Chondrocyte and cartilage biology
Other therapeutics
Online Access:http://link.springer.com/article/10.1186/s12967-017-1356-8

Internet

http://link.springer.com/article/10.1186/s12967-017-1356-8

Similar Items